174 related articles for article (PubMed ID: 34543124)
1. Novel Murine Pancreatic Tumor Model Demonstrates Immunotherapeutic Control of Tumor Progression by a Toxoplasma gondii Protein.
Payne SN; Emmerich PB; Davis NM; Deming DA; Knoll LJ
Infect Immun; 2021 Nov; 89(12):e0050821. PubMed ID: 34543124
[TBL] [Abstract][Full Text] [Related]
2. Toxoplasma gondii soluble tachyzoite antigen triggers protective mechanisms against fatal intestinal pathology in oral infection of C57BL/6 mice.
Benevides L; Cardoso CR; Milanezi CM; Castro-Filice LS; Barenco PV; Sousa RO; Rodrigues RM; Mineo JR; Silva JS; Silva NM
PLoS One; 2013; 8(9):e75138. PubMed ID: 24086456
[TBL] [Abstract][Full Text] [Related]
3. Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.
Sanders KL; Fox BA; Bzik DJ
Cancer Immunol Res; 2015 Aug; 3(8):891-901. PubMed ID: 25804437
[TBL] [Abstract][Full Text] [Related]
4. Plant Hsp90 is a novel adjuvant that elicits a strong humoral and cellular immune response against B- and T-cell epitopes of a Toxoplasma gondii SAG1 peptide.
Sánchez-López EF; Corigliano MG; Albarracín RM; Sander VA; Legarralde A; Bengoa-Luoni SA; Clemente M
Parasit Vectors; 2019 Mar; 12(1):140. PubMed ID: 30909938
[TBL] [Abstract][Full Text] [Related]
5. The virulence-related rhoptry protein 5 (ROP5) of Toxoplasma Gondii is a novel vaccine candidate against toxoplasmosis in mice.
Zheng B; Lu S; Tong Q; Kong Q; Lou D
Vaccine; 2013 Sep; 31(41):4578-84. PubMed ID: 23928460
[TBL] [Abstract][Full Text] [Related]
6. Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model.
Bahwal SA; Chen JJ; E L; Hao T; Chen J; Carruthers VB; Lai J; Zhou X
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2743-2757. PubMed ID: 35556163
[TBL] [Abstract][Full Text] [Related]
7. Radiation effects on
da Costa A; Nascimento ND; Galisteo AJ; Dias Dos Passos AB; de Andrade HF
Int J Radiat Biol; 2020 May; 96(5):697-706. PubMed ID: 31855098
[No Abstract] [Full Text] [Related]
8. Strain- and Dose-Dependent Reduction of
Jennes M; De Craeye S; Devriendt B; Dierick K; Dorny P; Cox E
Front Cell Infect Microbiol; 2017; 7():232. PubMed ID: 28642841
[No Abstract] [Full Text] [Related]
9. Secretory Microneme Proteins Induce T-Cell Recall Responses in Mice Chronically Infected with Toxoplasma gondii.
Saraav I; Wang Q; Brown KM; Sibley LD
mSphere; 2019 Feb; 4(1):. PubMed ID: 30814319
[TBL] [Abstract][Full Text] [Related]
10. The soluble tachyzoite antigen of Toxoplasma gondii has a protective effect on mouse allografts.
Wang S; Fang Z; Huang X; Luo X; Fang Z; Gong N; Ming C
Transplant Proc; 2013 Mar; 45(2):677-83. PubMed ID: 23267786
[TBL] [Abstract][Full Text] [Related]
11. Toxoplasma gondii soluble antigen induces a subset of lipopolysaccharide-inducible genes and tyrosine phosphoproteins in peritoneal macrophages.
Li ZY; Manthey CL; Perera PY; Sher A; Vogel SN
Infect Immun; 1994 Aug; 62(8):3434-40. PubMed ID: 8039914
[TBL] [Abstract][Full Text] [Related]
12. Immediate Interferon Gamma Induction Determines Murine Host Compatibility Differences between Toxoplasma gondii and Neospora caninum.
Coombs RS; Blank ML; English ED; Adomako-Ankomah Y; Urama IS; Martin AT; Yarovinsky F; Boyle JP
Infect Immun; 2020 Mar; 88(4):. PubMed ID: 32014892
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cell intrinsic toll-like receptor MyD88 signaling contributes to IL-12-dependent IFN-γ production by mice during infection with Toxoplasma gondii.
Ge Y; Chen J; Qiu X; Zhang J; Cui L; Qi Y; Liu X; Qiu J; Shi Z; Lun Z; Shen J; Wang Y
Int J Parasitol; 2014 Jun; 44(7):475-84. PubMed ID: 24727091
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of three recombinant multi-antigenic vaccines composed of surface and secretory antigens of Toxoplasma gondii in murine models of experimental toxoplasmosis.
Dziadek B; Gatkowska J; Brzostek A; Dziadek J; Dzitko K; Grzybowski M; Dlugonska H
Vaccine; 2011 Jan; 29(4):821-30. PubMed ID: 21087690
[TBL] [Abstract][Full Text] [Related]
15. C5aR1 Activation Drives Early IFN-γ Production to Control Experimental
Briukhovetska D; Ohm B; Mey FT; Aliberti J; Kleingarn M; Huber-Lang M; Karsten CM; Köhl J
Front Immunol; 2020; 11():1397. PubMed ID: 32733463
[No Abstract] [Full Text] [Related]
16. Secretion of Rhoptry and Dense Granule Effector Proteins by Nonreplicating Toxoplasma gondii Uracil Auxotrophs Controls the Development of Antitumor Immunity.
Fox BA; Sanders KL; Rommereim LM; Guevara RB; Bzik DJ
PLoS Genet; 2016 Jul; 12(7):e1006189. PubMed ID: 27447180
[TBL] [Abstract][Full Text] [Related]
17. Gamma irradiation of Toxoplasma gondii protein extract improve immune response and protection in mice models.
da Costa A; Zorgi NE; do Nascimento N; Galisteo AJ; de Andrade HF
Biomed Pharmacother; 2018 Oct; 106():599-604. PubMed ID: 29990848
[TBL] [Abstract][Full Text] [Related]
18. Toxoplasma gondii-Derived Synthetic Peptides Containing B- and T-Cell Epitopes from GRA2 Protein Are Able to Enhance Mice Survival in a Model of Experimental Toxoplasmosis.
Bastos LM; Macêdo AG; Silva MV; Santiago FM; Ramos EL; Santos FA; Pirovani CP; Goulart LR; Mineo TW; Mineo JR
Front Cell Infect Microbiol; 2016; 6():59. PubMed ID: 27313992
[TBL] [Abstract][Full Text] [Related]
19. C57BL/6 mice immunized with synthetic peptides from Toxoplasma gondii surface and microneme immunodominant antigens are able to decrease parasite burden in the brain tissues.
Barros HLS; Santana SS; Pajuaba ACAM; da Silva Cardoso Barros P; Dos Reis de Carvalho F; de Paiva VF; Wilson Patriarca Mineo T; Mineo JR
Acta Trop; 2019 Aug; 196():1-6. PubMed ID: 31059707
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the adjuvant effect of pidotimod on the immune protection induced by UV-attenuated Toxoplasma gondii in mouse models.
Zhao Y; Huang B; Huang S; Zheng H; Li YQ; Lun ZR; Shen J; Wang Y; Kasper LH; Lu F
Parasitol Res; 2013 Sep; 112(9):3151-60. PubMed ID: 23783399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
